Naoko OHTANI,Fumitaka KAMACHI,Tze Mun LOO,Shinichi KOIZUMI,Takako OKUMURA
申请号：
US15343999
公开号：
US20180125832A1
申请日:
2016.11.04
申请国别(地区):
US
年份:
2018
代理人:
摘要：
This invention is directed to prostaglandin E2 receptor 4 (EP4) antagonists useful in the treatment of nonalcoholic steatohepatitis (NASH)-associated liver cancer in a human or animal. The method comprises administering one or more of Compound A, Compound B or Compound C, or pharmaceutically acceptable salts thereof, as the EP4 antagonist(s). The method may include a pharmaceutical composition comprising the EP4 antagonist, and may include one or more other active agents and/or therapies.
